Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

SANTA CLARA, Calif., Aug.  26, 2020  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Shockwave management is scheduled to speak at the following upcoming virtual investor conferences:

Shockwave Medical to Participate in Upcoming September Investor Conferences

ShockWave Medical's (SWAV) CEO Doug Godshall on Q2 2020 Results - Earnings Call Transcript

SANTA CLARA, Calif., Aug.  11, 2020  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2020.

Shockwave Medical Reports Second Quarter 2020 Financial Results

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Shockwave Medical (SWAV) Q2 Earnings Expected to Decline

SANTA CLARA, Calif., July  30, 2020  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11 to 13, 2020.

Shockwave Medical to Present at the Canaccord Genuity 40th Annual Growth Conference

SANTA CLARA, Calif., July  21, 2020  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020. Company management will host a corresponding teleconference that will be webcasted live beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. 

Shockwave Medical to Report Second Quarter 2020 Financial Results on August 11, 2020

SANTA CLARA, Calif., July  20, 2020  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwave’s Compensation Committee. 

Shockwave Appoints Maria Sainz to Board of Directors

The company isn't taking the ruling lying down.

Shockwave Medical Stock Falls After Two Patents Ruled Invalid

SANTA CLARA, Calif., July  08, 2020  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company received the initial rulings related to two of the inter partes review (IPR) cases that were initiated by Cardiovascular Systems, Inc. (CSI).

Shockwave Announces Decisions From the U.S. Patent and Trademark Office on Inter Partes Review Proceeding

Abbott Labs

Intuitive Surgical

Catalysts are potentially on the way for these leading medical device stocks.

3 Top Medical-Device Stocks to Buy in the Second Half of 2020

SANTA CLARA, Calif., June  16, 2020  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 1,700,000 shares of its common stock at a price to the public of $45.75 per share. All of the shares are being offered by Shockwave. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Shockwave, are expected to be approximately $77.8 million. The offering is scheduled to close on June 19, 2020, subject to the satisfaction of customary closing conditions. The underwriters for the offering also have a 30-day option to purchase up to an additional 255,000 shares of Shockwave’s common stock at the price to the public, less underwriting discounts and commissions. Shockwave’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “SWAV.”

Shockwave Announces Pricing of Public Offering of Common Stock

SANTA CLARA, Calif., June  16, 2020  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced it has commenced an underwritten public offering of 1,700,000 shares of its common stock. All of the shares of common stock are being offered by Shockwave. In addition, Shockwave intends to grant the underwriters a 30-day option to purchase up to an additional 255,000 shares of its common stock. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Shockwave Announces Proposed Public Offering of Common Stock

Centers for Medicare & Medicaid Services Issues New Codes for Peripheral Intravascular Lithotripsy Performed in Hospital Outpatient and Inpatient Settings Centers for Medicare & Medicaid Services Issues New Codes for Peripheral Intravascular Lithotripsy Performed in Hospital Outpatient and Inpatient Settings

Shockwave Medical Announces That CMS Has Created New Codes for Intravascular Lithotripsy

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q1 2020 Results - Earnings Call Transcript

SANTA CLARA, Calif., May  12, 2020  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2020.

Shockwave Medical Reports First Quarter 2020 Financial Results

Shockwave Medical (SWAV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

DISRUPT CAD IV Clinical Study to Support Regulatory Device Approval in Japan DISRUPT CAD IV Clinical Study to Support Regulatory Device Approval in Japan

Shockwave Completes Enrollment of Coronary Intravascular Lithotripsy Study in Japan

Align Technology

Bausch Health Companies Inc

Optimism that the worst might be over with the COVID-19 outbreak fueled investors' enthusiasm for these healthcare stocks.

Why Align Technology, Bausch Health, Momenta Pharmaceuticals, and ShockWave Medical Stocks Soared Today

Last Patient Enrolled in DISRUPT CAD III, the U.S. FDA IDE Study for IVL in Severely Calcified Coronary Arteries Last Patient Enrolled in DISRUPT CAD III, the U.S. FDA IDE Study for IVL in Severely Calcified Coronary Arteries

SHOCKWAVE COMPLETES ENROLLMENT IN PIVOTAL STUDY FOR CORONARY INTRAVASCULAR LITHOTRIPSY

An analyst downgrade sparked a sell-off of the medical device maker.

Why ShockWave Medical Stock Is Sinking Today

DexCom

There's no better time than the present to scoop up shares of these high-growth medical device makers.

Got $5,000 to Invest? 3 Great Medical Device Stocks to Buy Right Now

Guardant Health Inc

Novocure

It was another brutal start to the trading week.

Why ShockWave Medical, Novocure, and Guardant Health Shares Tanked Today

Exact Sciences

Why Exact Sciences, Align Technology, and ShockWave Medical Shares Are Plunging Today

ShockWave Medical Expects To Reap Benefits Of 2019 Preparation

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q4 2019 Results - Earnings Call Transcript

News for Shockwave Medical Stock (SWAV)